Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.51 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16136364 | 0.89 | HSP90B1 (0.52) | SMN1; SMN2HSP90AA1HSP90B1LMNA | |
| SCHEMBL16136367 | 0.88 | HTT (0.40) | SMN1; SMN2HSP90AA1HSP90B1LMNAADRA2C | |
| SCHEMBL16136363 | 0.88 | LMNA (0.51) | HSP90AA1HSP90B1TP53LMNAAGTR1 | |
| SCHEMBL16064990 | 0.87 | HSP90B1 (0.54) | SMN1; SMN2NPC1RAB9AHSP90AA1HSP90B1 | |
| SCHEMBL16136298 | 0.86 | HSP90B1 (0.55) | SMN1; SMN2NPC1RAB9AHSP90AA1HSP90B1 | |
| SCHEMBL16133635 | 0.86 | HSP90AA1 (0.48) | SMN1; SMN2NPC1RAB9AHSP90AA1HSP90B1 | |
| SCHEMBL16136235 | 0.81 | BRD4 (0.47) | HSP90AA1HSP90B1TP53LMNAMAPT | |
| SCHEMBL16136366 | 0.81 | HSP90AA1 (0.53) | SMN1; SMN2HSP90AA1HSP90B1TP53LMNA | |
| SCHEMBL16136339 | 0.78 | HSP90AA1 (0.54) | SMN1; SMN2NPC1RAB9AHSP90AA1HSP90B1 | |
| SCHEMBL16136301 | 0.77 | HSP90AA1 (0.51) | SMN1; SMN2NPC1RAB9AHSP90AA1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776996-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160326170-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2016-11-10 | — | — | US | disclosed |
| US-9365570-B2 | Substituted 6, 5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2016-01-28 | — | — | US | disclosed |
| US-20150246916-A1 | Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-09-03 | — | — | US | disclosed |
| US-9045477-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140296283-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024081-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | SMN1; SMN2 4624/4885NPC1 197/4885RAB9A 2187/4885 |
| US-20150246916-A1 | Substituted 6, 5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | SMN1; SMN2 4624/4885NPC1 197/4885RAB9A 2187/4885 |
| US-20140296283-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, PAICS, CYP4B1 | SMN1; SMN2 4624/4885NPC1 197/4885RAB9A 2187/4885 |
| US-20160326170-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, PAICS, CYP4B1 | SMN1; SMN2 4624/4885NPC1 197/4885RAB9A 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.